Administration of Nirsevimab for RSV Prophylaxis in Infants: A Comprehensive Review
VaccinesRespiratory syncytial virus (RSV) is the primary etiological agent responsible for lower respiratory tract infections (LRTIs) and hospitalizations among infants. Nirsevimab, a novel monoclonal antibody (mAb), offers sustained protection against RSV for a
Fangrui Ding
exaly +6 more sources
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants [PDF]
New England Journal of Medicine, 2023 The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab on hospitalizations for respiratory syncytial virus (RSV)-associated lower respiratory tract infection when administered in healthy infants are unclear.In a pragmatic trial, we randomly assigned, in a 1:1 ratio, infants who were 12 months of age or younger, had been born at a
Pierre Tissières +2 more
exaly +10 more sources
Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain [PDF]
VaccinesBackground/Objectives: Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Nirsevimab has demonstrated to be a promising tool for preventing severe RSV disease.
Sara Jimeno +2 more
exaly +4 more sources
The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis [PDF]
Frontiers in Pediatrics, 2023 BackgroundRespiratory syncytial virus (RSV) is a leading cause of morbidity and mortality among infants with a global incidence of 9.5% and a mortality rate of 2.2%. The management of RSV infection is mainly supportive and, aside from emerging monoclonal
Christian Wilson Turalde
exaly +4 more sources
Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria [PDF]
Frontiers in Public HealthBackgroundSince summer 2024, passive immunization with nirsevimab (Beyfortus®) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection.
Griesmaier Elke +2 more
exaly +4 more sources
Nature Communications, 2023 Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV) fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV ...
Bahar Ahani +20 more
doaj +2 more sources
Post-licensure safety of nirsevimab from the Canadian National Vaccine Safety (CANVAS) network [PDF]
Human Vaccines & ImmunotherapeuticsAlthough clinical trials have shown that nirsevimab is safe, post-licensure safety data from routine clinical settings are lacking. This study describes parent-reported health events occurring within seven days of nirsevimab administration.
Marina Viñeta Paramo +11 more
doaj +2 more sources
Multicentre study on nirsevimab: Bayesian analysis reveals persisting risk for preterm infants [PDF]
BMJ Paediatrics OpenObjective To evaluate whether the timing and effectiveness of nirsevimab prophylaxis vary by gestational age.Design Retrospective cohort study conducted during two identical epidemic seasons: 2023–2024 (before nirsevimab introduction) and 2024–2025 ...
Federico Marchetti +13 more
doaj +2 more sources
Real-world impact of nirsevimab on RSV hospitalizations in children under 2 years of age: retrospective monocentric study in a large German tertiary pedatric center [PDF]
Molecular and Cellular PediatricsBackground Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization among infants and young children. Broad immunization with the monoclonal antibody nirsevimab represents a promising preventive strategy. However, real-world data
Moritz Bauer +4 more
doaj +2 more sources
Clinical and Translational ScienceRespiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) in infants worldwide. Nirsevimab, an extended half‐life monoclonal antibody against RSV, is approved in China for the prevention of RSV lower respiratory ...
Xiaomeng Mao +12 more
doaj +2 more sources